Genetic Subtypes: SLC25A38, TRNT1, and Others
At a Glance
In autosomal recessive congenital sideroblastic anemia, the gene subtype helps predict whether a child will mainly have severe anemia or may also develop fevers, immune problems, developmental delays, or heart, hearing, vision, or kidney concerns, guiding monitoring and family planning.
While all forms of Autosomal Recessive Congenital Sideroblastic Anemia (AR-CSA) share the same hallmark—ring sideroblasts in the bone marrow—the underlying genetic “glitch” can vary significantly from one child to another [1][2]. The specific gene that is mutated acts as a roadmap for your child’s medical team, helping them predict whether the condition will affect only the blood or potentially involve other parts of the body [3].
The Blueprint: Autosomal Recessive Inheritance
To understand these subtypes, it helps to recall how they are inherited. In autosomal recessive conditions, a child must inherit two altered copies (pathogenic variants) of a specific gene—one from each parent—to develop the disorder [4][5].
- Carriers: Parents are typically “carriers,” meaning they have one healthy copy of the gene and one altered copy. Carriers usually show no signs of the disease and are healthy [4].
- The 25% Rule: When both biological parents carry pathogenic variants in the same gene, there is a 25% chance with each pregnancy that the child will inherit both altered copies and have AR-CSA [4][6]. This rule changes if a variant is uncertain, one parent is affected, or the mutation is a new de novo event.
SLC25A38: The Most Common Form
The SLC25A38 pathogenic variant is the most frequent cause of recessive sideroblastic anemia [7]. This gene provides the instructions for a “transport protein” that carries essential ingredients into the mitochondria to make heme [8].
- Possible Presentation: This subtype often appears very early in life; in some cohorts, the median presentation was in infancy (6 months) [1].
- Variable Severity: It often causes a severe form of microcytic anemia (small red blood cells) that can become transfusion-dependent, meaning the child will need regular blood transfusions to maintain healthy oxygen levels [9][10].
- Scope: For most children, this subtype is “non-syndromic,” meaning it primarily affects the blood and bone marrow, though careful monitoring for iron overload is essential [1][7].
TRNT1 and SIFD: A Multisystem Subtype
The TRNT1 pathogenic variant is unique because it often affects much more than just the blood. It can cause a syndrome known as SIFD, which stands for the four main symptoms often seen together [2]:
- Sideroblastic anemia (the blood disorder).
- Immunodeficiency (specifically low B-cells, making it harder to fight infections).
- Fevers (periodic or recurrent fevers that aren’t always caused by an infection).
- Developmental delay (which can include neurologic issues or motor skill delays).
Because the TRNT1 gene is involved in making proteins throughout the body, children with this subtype may also face variable challenges with their vision, hearing, heart, or kidneys [3][11]. The severity can vary widely; some children have very mild symptoms, while others require intensive, multi-specialty care [3][12].
HSPA9 and GLRX5: Rare Metabolic Glitches
These two genes are involved in a process called iron-sulfur cluster biogenesis. This is a fancy way of saying they help the cell manage iron and “switch on” the machinery needed for heme production [13][14].
- HSPA9: This pathogenic variant is very rare. Some cases have been documented, and genetic counseling is crucial for understanding inheritance [13].
- GLRX5: While this often presents as an isolated anemia, some rare cases have been linked to more serious “syndromic” issues, such as neurologic problems, heart muscle weakness (cardiomyopathy), or metabolic imbalances [14][15][16].
Why Subtypes Matter for Your Child
Identifying the exact genetic subtype is one of the most important steps in your child’s care. It tells your medical team:
- What to monitor: Does your child need regular heart ultrasounds, hearing tests, or immune system checks? [3]
- Treatment intensity: Is your child likely to need early transfusions, or can they be managed with other therapies? [1]
- Future planning: Knowing the specific gene allows for accurate testing of siblings and provides clear information for family planning [17][5].
| Gene | Primary Type | Possible Features to Watch |
|---|---|---|
| SLC25A38 | Non-Syndromic | Severe anemia in infancy; high risk of iron overload [1]. |
| TRNT1 | Syndromic (SIFD) | Anemia plus fevers, low immunity, and potential developmental delays [2]. Not all patients exhibit all features. |
| HSPA9 | Non-Syndromic | Rare form of anemia; limited data on long-term systemic effects [13]. |
| GLRX5 | Variable | Usually isolated anemia, but can occasionally affect the brain or heart [14][15]. |
If your child’s genetic report is unclear, or if they have symptoms that don’t seem to match their “assigned” subtype, it is important to discuss this with a pediatric geneticist or hematologist [17]. Genes often surprise us, and your child’s specific journey may involve a unique combination of these factors.
Common questions in this guide
What does autosomal recessive inheritance mean for my child?
Which genes are linked to autosomal recessive congenital sideroblastic anemia?
How does SLC25A38-related disease differ from TRNT1-related SIFD?
Could my child’s genetic subtype affect organs beyond the blood?
How likely is iron overload with a genetic subtype of AR-CSA?
Why does the exact gene matter for siblings and future pregnancies?
Get notified when new evidence is published on Autosomal recessive sideroblastic anemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Clinical characterization and hematopoietic stem cell transplant outcomes for congenital sideroblastic anemia caused by a novel pathogenic variant in SLC25A38.
Uminski K, Houston DS, Hartley JN, et al.
Pediatric blood & cancer 2020; (67(10)):e28623 doi:10.1002/pbc.28623.
PMID: 32790119 - 2
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).
Li Y, Deng M, Han T, et al.
Journal of clinical immunology 2023; (43(4)):780-793 doi:10.1007/s10875-023-01441-7.
PMID: 36729249 - 3
Clinical and Therapeutic Aspects of Sideroblastic Anaemia with B-Cell Immunodeficiency, Periodic Fever and Developmental Delay (SIFD) Syndrome: a Systematic Review.
Maccora I, Ramanan AV, Wiseman D, et al.
Journal of clinical immunology 2023; (43(1)):1-30 doi:10.1007/s10875-022-01343-0.
PMID: 35984545 - 4
Autosomal recessive frameshift variant broadens HECW2-related disease spectrum.
Dehghanzad R, Eshaghkhani Y, Saberi M, et al.
European journal of medical genetics 2025; (77()):105036 doi:10.1016/j.ejmg.2025.105036.
PMID: 40812465 - 5
A Rare Cause of Primary Microcephaly: 4 New Variants in CDK5RAP2 Gene and Review of the Literature.
Erdogan M, Unal A, Dogan ME, et al.
American journal of medical genetics. Part A 2025; (197(9)):e64072 doi:10.1002/ajmg.a.64072.
PMID: 40243280 - 6
Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options.
Abu-Zeinah G, DeSancho MT
Journal of blood medicine 2020; (11()):305-318 doi:10.2147/JBM.S232644.
PMID: 33061728 - 7
SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature.
Heeney MM, Berhe S, Campagna DR, et al.
Human mutation 2021; (42(11)):1367-1383 doi:10.1002/humu.24267.
PMID: 34298585 - 8
Characterization of Human and Yeast Mitochondrial Glycine Carriers with Implications for Heme Biosynthesis and Anemia.
Lunetti P, Damiano F, De Benedetto G, et al.
The Journal of biological chemistry 2016; (291(38)):19746-59 doi:10.1074/jbc.M116.736876.
PMID: 27476175 - 9
Genotype/phenotype correlations of childhood-onset congenital sideroblastic anaemia in a European cohort.
Fouquet C, Le Rouzic MA, Leblanc T, et al.
British journal of haematology 2019; (187(4)):530-542 doi:10.1111/bjh.16100.
PMID: 31338833 - 10
Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.
Cazzola M, Malcovati L
Hematology. American Society of Hematology. Education Program 2015; (2015()):19-25 doi:10.1182/asheducation-2015.1.19.
PMID: 26637696 - 11
SIFD as a novel cause of severe fetal hydrops and neonatal anaemia with iron loading and marked extramedullary haemopoiesis.
Barton C, Kausar S, Kerr D, et al.
Journal of clinical pathology 2018; (71(3)):275-278 doi:10.1136/jclinpath-2017-204698.
PMID: 29055896 - 12
Expanding the Phenotype of TRNT1-Related Immunodeficiency to Include Childhood Cataract and Inner Retinal Dysfunction.
Hull S, Malik AN, Arno G, et al.
JAMA ophthalmology 2016; (134(9)):1049-53 doi:10.1001/jamaophthalmol.2015.5833.
PMID: 27389523 - 13
Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9.
Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, et al.
Blood 2015; (126(25)):2734-8 doi:10.1182/blood-2015-09-659854.
PMID: 26491070 - 14
GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia.
Daher R, Mansouri A, Martelli A, et al.
Molecular genetics and metabolism 2019; (128(3)):342-351 doi:10.1016/j.ymgme.2018.12.012.
PMID: 30660387 - 15
Infant With a Severe Form of GLRX5-Related Atypical Hyperglycinemia Exhibiting Novel Cardiac and Neurologic Disease Manifestations at Autopsy.
Ferreira EO, Del Bigio MR, Morin J, Frosk P
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2025; (28(5)):390-394 doi:10.1177/10935266251335065.
PMID: 40415601 - 16
Mitochondrial iron-sulfur cluster biogenesis from molecular understanding to clinical disease.
Alfadhel M, Nashabat M, Abu Ali Q, Hundallah K
Neurosciences (Riyadh, Saudi Arabia) 2017; (22(1)):4-13 doi:10.17712/nsj.2017.1.20160542.
PMID: 28064324 - 17
The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes.
Monies D, Abouelhoda M, AlSayed M, et al.
Human genetics 2017; (136(8)):921-939 doi:10.1007/s00439-017-1821-8.
PMID: 28600779
This page is for informational purposes only and does not constitute medical advice. A pediatric hematologist or geneticist should interpret your child’s genetic results and recommend monitoring.